诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVS 诺华

未开盘 02-18 16:00:00 EST

165.38

-0.79

-0.48%

盘后165.00

-0.38-0.23%

19:24 EST

最高167.86	最低164.71	成交量237.96万
今开167.57	昨收166.17	日振幅1.90%
总市值3,155亿	流通市值3,003亿	总股本19.08亿
成交额3.94亿	换手率0.13%	流通股本18.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":165.38,"timestamp":1771448400000,"preClose":166.17,"halted":0,"volume":2379624,"hourTrading":{"tag":"盘后","latestPrice":165,"preClose":165.38,"latestTime":"19:24 EST","volume":184971,"amount":30590726.08,"timestamp":1771460687626,"change":-0.38,"changeRate":-0.002298,"amplitude":0.0052},"delay":0,"changeRate":-0.0047541674189083,"floatShares":1816000000,"shares":1907999999,"eps":7.15,"marketStatus":"未开盘","change":-0.79,"latestTime":"02-18 16:00:00 EST","open":167.57,"high":167.86,"low":164.705,"amount":394164988.51703995,"amplitude":0.018987,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.15,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771491600000},"marketStatusCode":0,"adr":1,"adrRate":1,"exchange":"NYSE","adjPreClose":166.17,"dividendRate":0.024163,"preHourTrading":{"tag":"盘前","latestPrice":167.55,"preClose":166.17,"latestTime":"09:29 EST","volume":25393,"amount":4251886.19332,"timestamp":1771424999071,"change":1.38,"changeRate":0.008305,"amplitude":0.005777},"postHourTrading":{"tag":"盘后","latestPrice":165,"preClose":165.38,"latestTime":"19:24 EST","volume":184971,"amount":30590726.08,"timestamp":1771460687626,"change":-0.38,"changeRate":-0.002298,"amplitude":0.0052},"volumeRatio":0.879363,"impliedVol":0.2644,"impliedVolPercentile":0.7928},"requestUrl":"/m/hq/s/NVS/tweets","defaultTab":"tweets","newsList":[{"id":"2612147565","title":"产业新闻 | 礼来单抗/多肽药物组合达3期临床主要终点；穿越血脑屏障！新锐推进新一代阿尔茨海默病疗法……","url":"https://stock-news.laohu8.com/highlight/detail?id=2612147565","media":"药明康德","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612147565?lang=zh_cn&edition=full","pubTime":"2026-02-19 07:30","pubTimestamp":1771457447,"startTime":"0","endTime":"0","summary":"礼来单抗/多肽药物组合达3期临床主要终点礼来今日宣布，TOGETHER-PsO临床3b期研究取得积极顶线结果。安全性方面，联合用药相关不良事件总体为轻至中度，与两种药物既往已知安全性特征一致。新锐推进潜在“best-in-class”阿尔茨海默病疗法Korsana Biosciences今日宣布结束隐匿模式并公开亮相。此次合作将整合UNP以人工智能增强的大环肽分子平台与诺华在全球药物开发及商业化方面的能力，共同开发下一代治疗药物，潜在应用方向包括心血管疾病领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021907424697a678e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021907424697a678e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B775H168.HKD","LU0889565916.HKD","LU0432979614.USD","LU0109394709.USD","LU2462157665.USD","LU1548497426.USD","IE00B7KXQ091.USD","LU2324357040.USD","SG9999014906.USD","LU1814569148.SGD","LU2756315664.SGD","LU0354030511.USD","BK4516","LU2237438978.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU1720051108.HKD","SGXZ81514606.USD","LU2089984988.USD","GB00BDT5M118.USD","LU0456855351.SGD","LU1064131342.USD","LU0786609619.USD","IE00BK4W5L77.USD","BK4534","LU1623119135.USD","SG9999015945.SGD","LU0203202063.USD","LU2896262040.SGD","BK4533","LU2746668974.SGD","LU0256863902.USD","IE00BJJMRZ35.SGD","LU2491049909.HKD","LU2360106947.USD","LU2028103732.USD","LU0689472784.USD","LU2471134879.HKD","LU1551013342.USD","LU2087625088.SGD","LU1974910355.USD","LU2213496289.HKD","LU0320765059.SGD","IE0005OL40V9.USD","IE00BJJMRX11.SGD","LU2168563687.JPY","LU2471134952.CNY","SG9999015986.USD","BK4599","LU1629891620.HKD","LU0882574055.USD","LU0385154629.USD","IE00BN29S564.USD","LU2023250330.USD","LU2471134523.USD","LU0640476718.USD","LU2168564065.EUR","LU1145028129.USD","LU0198837287.USD","IE00BJT1NW94.SGD","SG9999014898.SGD","LU0708995401.HKD","LU0289739699.SGD","LU1093756325.SGD","SGXZ99366536.SGD","LU1035775433.USD","LU1868836591.USD","LU2552382132.HKD","LU0353189763.USD","LU2211815571.USD","LU2168564149.EUR","LU0943347566.SGD","LU1868836757.USD","LU2271345857.HKD","LU2491050154.USD","LU2602419157.SGD","BK4007","LU2361044865.SGD","LU0061475181.USD","LU1983299246.USD","LU0471298777.SGD","LU2089283258.USD","LU1366192091.USD","LLYZ","SG9999015978.USD","LU1267930730.SGD","LU0109391861.USD","LU2750360997.AUD","LU1061106388.HKD","IE0004445239.USD","SGXZ57979304.SGD","SG9999018857.SGD","BK4585","LU1720051017.SGD","SG9999001176.SGD","LU1093756168.USD","LU1323610961.USD","IE00B1XK9C88.USD","LU0106261372.USD","SGXZ51526630.SGD","IE0002141913.USD","LU2237443549.SGD","LU0079474960.USD","IE0009355771.USD","LU1988902786.USD","LU0210536198.USD","LU2237443382.USD","LU0323591593.USD","IE00BJJMRY28.SGD","LU2237443895.HKD","LU0471298694.HKD","LU2468319806.SGD","LU2417539215.USD","SG9999017495.SGD","LU2264538146.SGD","LU1232071149.USD","LU2236285917.USD","LU1712237335.SGD","NVS","IE00BJLML261.HKD","LU0006306889.USD","LU1280957306.USD","LU0417517546.SGD","LU2112291526.USD","LU2168564222.USD","LU0823416689.USD","LU0820561818.USD","ELIS","LU0466842654.USD","LU1868837136.USD","LU2237443465.HKD","SG9999001176.USD","SG9999014914.USD","LU2552382215.SGD","LU0823434740.USD","LU2491050071.SGD","IE00B2B36J28.USD","LU0225283273.USD","LU0234572021.USD","LU2756315318.SGD","SGXZ31699556.SGD","LU0256863811.USD","LU0096364046.USD","LU2023250504.SGD","LU1057294990.SGD","BK4581","LU0158827781.USD","LU2456880835.USD","LU0114720955.EUR","LU1868837300.USD","LU0683600562.USD","LU0823434583.USD","LU2361044949.HKD","IE00BFSS7M15.SGD","LU0266013472.USD","LU0203201768.USD","LU0316494557.USD","LU2168564495.EUR","SG9999018865.SGD","LU0820561909.HKD","LU1989771016.USD","LU0158827948.USD","LU2361045086.USD","LU0094547139.USD","LU0320765992.SGD","LU0672654240.SGD","SG9999014880.SGD","IE00BKDWB100.SGD","LU2111349929.HKD","LU2552382058.USD","LU2106854487.HKD","LU2471134796.USD","LU0354030438.USD","LU1868836914.USD","SG9999015952.SGD","LU2461242641.AUD","IE00BKPKM429.USD","LU0058720904.USD","ELIL","LU0882574139.USD","LU2089284900.SGD","IE0004445015.USD","IE00BWXC8680.SGD","LU1291159041.SGD","SG9999013999.USD","LU2265009873.SGD","IE00B4JS1V06.HKD","LU2750360641.GBP","IE00B1BXHZ80.USD","LU0122379950.USD","LU0820562030.AUD","IE00BK4W5M84.HKD","LU1127390331.HKD","LU0238689110.USD","LU2746668461.USD","LU0097036916.USD","LU1551013425.SGD","LU2023251221.USD","LU1804176565.USD","LU2108987350.USD","LU2357305700.SGD","IE00BFSS8Q28.SGD","LLYX","IE00BFTCPJ56.SGD","LU0353189680.USD","BK4588","LU0964807845.USD","LU1069344957.HKD","LU1917777945.USD","LLY","LU2063271972.USD","LU2237443622.USD","LU0787776722.HKD","LU2237443978.SGD"],"gpt_icon":1},{"id":"2611486068","title":"超级大洗牌！跨国药企中国市场最新排名","url":"https://stock-news.laohu8.com/highlight/detail?id=2611486068","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611486068?lang=zh_cn&edition=full","pubTime":"2026-02-16 23:02","pubTimestamp":1771254130,"startTime":"0","endTime":"0","summary":"1月份，跨国药企基本都披露了2025年业绩。礼来则以45%的增幅，营收达651.79亿美元成功反超默沙东，排名第三。而在中国市场，2025年1月，替尔泊肽降糖和减重两项适应症相继上市。2022年至2024年，阿斯利康与默沙东争夺跨国药企中国区营收的“NO.1”，“销售一哥”的宝座每年轮流坐庄。此外，诺华已宣布在中国建立核药生产基地，以支持“派威妥”等放射性药物在中国市场的长期供应。跨国药企把全球创新好药带到中国，才是最好的市场策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","ASHR","LU1093756325.SGD","BK4504","BK4599","MCHI","LU1093756168.USD","LLY","BK4585","NVOX","ASHS","IE00BKVL7J92.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","NVO","DRAG","KWEB","NVS","MRK","BK4532","RHHBY","NVOH","AZN","BK4614","BK4007","CQQQ","CWEB","LU0963586101.USD"],"gpt_icon":1},{"id":"2609463565","title":"诺华制药2025财年实现净利润140.56亿美元，同比增加17.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609463565","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609463565?lang=zh_cn&edition=full","pubTime":"2026-02-07 00:01","pubTimestamp":1770393679,"startTime":"0","endTime":"0","summary":"2月7日，诺华制药公布财报，公告显示公司2025财年净利润为140.56亿美元，同比增加17.78%；其中营业收入为548.11亿美元，同比增加8.99%，每股基本收益为7.25美元。从资产负债表来看，诺华制药总负债690.20亿美元，其中短期债务57.84亿美元，资产负债比为0.01，流动比率为1.12。机构评级：截至2026年2月7日，当前有24家机构对诺华制药目标价做出预测，其中目标均价为145.67美元，其中最低目标价为109.51美元，最高目标价为175.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000135a485507c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000135a485507c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVS"],"gpt_icon":0},{"id":"2609554115","title":"诺华制药(NVS.US)全球首创自免新药在中国申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2609554115","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609554115?lang=zh_cn&edition=full","pubTime":"2026-02-06 14:48","pubTimestamp":1770360522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月6日，CDE网站显示，诺华制药(NVS.US)的伊利尤单抗(ianalumab)在中国申报上市。伊利尤单抗是诺华收购(MorphoSys)获得的一款靶向B淋巴细胞活化因子受体(BAFF-R)的全人源单抗，具有耗竭B细胞和抑制BAFF-R的双重作用机制，可用于治疗干燥综合征、免疫性血小板减少症(ITP)、系统性红斑狼疮(SLE)等多种自免疾病。该药物是首个完成III期研究的抗BAFF-R抗体。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0208291251.USD","BK4578","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0320765489.SGD","LU0070302665.USD","BK4532","IE00B2B36J28.USD","BK4588","IE00BJT1NW94.SGD","01477","IE0002141913.USD","IE00BFTCPJ56.SGD","NVS","BK4585","IE0009355771.USD","BK4007","BK1574","BK1191","LU0211331839.USD"],"gpt_icon":0},{"id":"2609347749","title":"诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2609347749","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609347749?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:49","pubTimestamp":1770270542,"startTime":"0","endTime":"0","summary":"【诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心】“毫无疑问，中国不仅已经成为像诺华这样的大型制药公司极为重要的市场，同时也正在迅速成长为一个全球性的研发与生物科技中心。”2月4日，诺华（NVS.US）首席执行官万思瀚在财报会上表达了上述观点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642639990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642639990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BJT1NW94.SGD","BK4578","LU0070302665.USD","LU0320765489.SGD","BK4532","IE0002141913.USD","IE00B2B36J28.USD","159837","BK4588","NVS","IE00BFTCPJ56.SGD","LU0208291251.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4007","LU0211331839.USD","IE00B4R5TH58.HKD","LABU","BK4585"],"gpt_icon":0},{"id":"2608013353","title":"仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2608013353","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608013353?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:48","pubTimestamp":1770191316,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月4日美股盘前，诺华制药公布2025年第四季度业绩。诺华公司预计今年利润将出现下滑，原因是公司的部分畅销药物将进一步受到仿制药竞争冲击。随着Entresto及其他老牌畅销药受到仿制药竞争者冲击，首席执行官Vas Narasimhan专注于创新药物的战略今年将面临考验。诺华已承诺在美国新建七处生产设施，这是其斥资230亿美元扩大该国制造规模计划的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BJJMRZ35.SGD","BK4007","BK4532","01477","IE00BJT1NW94.SGD","LU0070302665.USD","BK1574","BK4585","BK4588","BK1191","IE00BFTCPJ56.SGD","NVS","LU0211331839.USD","IE0009355771.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","BK4578","IE0002141913.USD","LU0208291251.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2608554332","title":"诺华：Q4核心净利润38.9亿美元，高于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608554332","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608554332?lang=zh_cn&edition=full","pubTime":"2026-02-04 14:02","pubTimestamp":1770184975,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0070302665.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4578","IE00BJT1NW94.SGD","BK4588","IE00B4R5TH58.HKD","IE00B2B36J28.USD","NVS","BK4007","LU0320765489.SGD","LU0211331839.USD","BK4585","IE00BJJMRZ35.SGD","LU0208291251.USD","IE0009355771.USD","BK4532"],"gpt_icon":0},{"id":"2608843538","title":"诺华可善挺（司库奇尤单抗）放射学阴性中轴型脊柱关节炎（nr-axSpA）适应症在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2608843538","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608843538?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:58","pubTimestamp":1770087491,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺华集团公众号2月3日宣布，其创新生物制剂可善挺?（司库奇尤单抗）新适应症获得国家药品监督管理局批准，适用于治疗对非甾体类抗炎药（NSAID）应答不佳的活动性放射学阴性中轴型脊柱关节炎成人患者（其客观征象表现为C反应蛋白（CRP）升高和/或磁共振成像（MRI）证据）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602033639802448.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033639802448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","NVS","LU0070302665.USD","LU0320765489.SGD","BK4532","BK4578","IE00BFTCPJ56.SGD","BK4585","IE0009355771.USD","LU0211331839.USD","BK4007","LU0208291251.USD","BK4588"],"gpt_icon":0},{"id":"2606711156","title":"诺华制药(NVS.US)siRNA疗法“英克司兰”获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2606711156","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606711156?lang=zh_cn&edition=full","pubTime":"2026-01-28 21:15","pubTimestamp":1769606154,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月28日，诺华制药(NVS.US)宣布其全球首创小干扰RNA降胆固醇药物乐可为®(英克司兰钠注射液)获中国国家药品监督管理局(NMPA)批准，作为饮食的辅助疗法，单药用于成人原发性高胆固醇血症(非家族性)或混合型血脂异常的患者，以降低低密度脂蛋白胆固醇(LDL-C)。英克司兰在此前已获批的与他汀类药物、或者与他汀类药物及其他降脂疗法联合用药适应症的基础上，进一步覆盖了更多有需要的血脂异常患者。作为全球首款也是目前唯一获批的一款靶向PCSK9的小干扰RNA降胆固醇药物，英克司兰一年两针的给药方式，有望提升治疗依从性及LDL-C的长期达标率，助力实现血脂的长期规范化管理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4588","LU0320765489.SGD","IE00B4R5TH58.HKD","BK4578","01477","BK4585","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0070302665.USD","IE00BJT1NW94.SGD","NVS","BK4532","IE0009355771.USD","BK4007","BK1191","LU0208291251.USD"],"gpt_icon":0},{"id":"1158049890","title":"财报前瞻｜诺华本季度营收预计增5.72%，机构观点以偏积极为主","url":"https://stock-news.laohu8.com/highlight/detail?id=1158049890","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158049890?lang=zh_cn&edition=full","pubTime":"2026-01-28 10:02","pubTimestamp":1769565747,"startTime":"0","endTime":"0","summary":"诺华将在2026年02月04日发布最新季度财报，市场关注收入与盈利的同步扩张及核心产品组合的提质与优化带来的利润改善与现金流稳健性。市场一致预期本季度诺华总收入为135.44亿美元，同比增5.72%；调整后每股收益为1.96美元，同比增8.26%；息税前利润为45.89亿美元，同比增7.12%。目前未形成针对本季度毛利率与净利率的公开一致预测，原因是机构在口径上存在差异且尚无统一披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜诺华本季度营收预计增5.72%，机构观点以偏积极为主","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"gpt_icon":0},{"id":"2605247377","title":"直击达沃斯丨医渡科技(02158)、文莱卫生部、诺华基金会宣布启动AI驱动的国家级心血管疾病防控项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2605247377","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605247377?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:30","pubTimestamp":1769160649,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年世界经济论坛年会上，诺华公司董事会主席Giovanni Caforio博士宣布一项重要合作：诺华基金会、文莱卫生部、医渡科技旗下EVYD公司将联合实施数智驱动的心血管疾病防控项目——CARDIO4Cities。当前，心血管疾病及其他非传染性疾病已成为全球死亡的主要原因，占比超70%。文莱国内心血管疾病更是主要死亡原因，给当地公共卫生体系带来持续压力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1518","BK1617","BK4007","BK1189","BK4588","IE00B4R5TH58.HKD","BK4585","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0211331839.USD","LU0208291251.USD","IE0002141913.USD","02158","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0320765489.SGD","LU0070302665.USD","NVS","BK4532","BK4578"],"gpt_icon":0},{"id":"2603691636","title":"FDA概述细胞/基因疗法CMC灵活性 可能对诺华与辉瑞有利","url":"https://stock-news.laohu8.com/highlight/detail?id=2603691636","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603691636?lang=zh_cn&edition=full","pubTime":"2026-01-14 00:01","pubTimestamp":1768320060,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）详细说明了为加速细胞与基因治疗开发而定制的生产与控制让步措施，同时保持标准，这可能对诺华（NVS）和辉瑞（PFE）等开发商构成潜在利好。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-14/doc-inhheupf5646437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443895.HKD","IE00BZ1G4Q59.USD","BK4550","LU0225284248.USD","IE00BKVL7J92.USD","LU1066053197.SGD","IE00BLSP4239.USD","LU0289739699.SGD","LU0456855351.SGD","IE00BFXG1179.USD","BK4533","IE0009355771.USD","LU0306806265.USD","LU2237443465.HKD","SG9999002224.SGD","LU0122379950.USD","BK4581","BK4006","LU0170899867.USD","BK4592","LU0321505439.SGD","BK4007","SGXZ57979304.SGD","LU0971096721.USD","LU2237443382.USD","SG9999013999.USD","LU0070302665.USD","SG9999001176.USD","BK4585","LU0211331839.USD","LU1023059063.AUD","IE00BLSP4452.SGD","BK4568","LU2746668461.USD","IE00B19Z3B42.SGD","LU2746668974.SGD","LU0306807586.USD","LU0882574139.USD","LU0208291251.USD","LU1363072403.SGD","LU2237443549.SGD","SG9999003800.SGD","IE0002141913.USD","IE000M9KFDE8.USD","LU0234572021.USD","IE00B1BXHZ80.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","SG9999001176.SGD","IE00B4R5TH58.HKD","LU2237443978.SGD","IE00B19Z3581.USD","LU0149725797.USD","LU0985481810.HKD","LU0267386448.USD","SG9999011175.SGD","BK4534","NVS","LU0058720904.USD","LU1066051498.USD","BK4599","LU1883839398.USD","LU0225771236.USD","IE00BJT1NW94.SGD","LU1894683264.USD","IE00BFTCPJ56.SGD","LU2237443622.USD","IE00BBT3K403.USD","LU1894683348.USD","SG9999002232.USD","BK4578","IE00BHPRN162.USD","LU0321505868.SGD","LU1057294990.SGD","IE0002270589.USD","BK4532","BK4588","PFE","LU0320765489.SGD","LU0868494617.USD"],"gpt_icon":0},{"id":"2602640541","title":"赛诺神经与诺华签署17亿美元许可协议 合作开发阿尔茨海默病治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2602640541","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602640541?lang=zh_cn&edition=full","pubTime":"2026-01-12 23:24","pubTimestamp":1768231440,"startTime":"0","endTime":"0","summary":"生物科技企业赛诺神经制药公司于周一宣布，已与瑞士制药巨头诺华达成一项价值近 17 亿美元的许可协议，双方将合作开发用于治疗阿尔茨海默病的潜在抗体疗法。　　通过这项协议，诺华将获得赛诺神经一项核心专有技术的使用权，该技术旨在优化药物向大脑的递送效率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-12/doc-inhhamhf8113709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVS","BK4007","IE00BJJMRZ35.SGD","LU0211331839.USD","IE00BJT1NW94.SGD","LU0070302665.USD","BK4578","BK4588","IE0009355771.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0320765489.SGD","BK4585","IE00B4R5TH58.HKD","BK4532","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2602592441","title":"中晟全肽与诺华就一款放射性配体疗法资产签署全球授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2602592441","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602592441?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:15","pubTimestamp":1768205749,"startTime":"0","endTime":"0","summary":"每经AI快讯，湖南中晟全肽生物科技股份有限公司1月12日通过公众号宣布，公司已与诺华就放射性配体疗法领域一款未披露的多肽类资产达成全球授权与合作协议。根据协议，诺华获得该资产的全球独家授权，并将主导后续所有研发及商业化相关工作。根据协议条款，中晟全肽将获得5000万美元首付款，并有资格获得后续研发、监管及销售里程碑付款，同时有权就未来全球净销售额享受分级特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601123615775823.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601123615775823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVS","IE00B4R5TH58.HKD","IE0009355771.USD","LU0070302665.USD","IE00B2B36J28.USD","IE0002141913.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","LU0211331839.USD","BK4578","BK4585","BK4007","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0208291251.USD","BK4532","BK4588"],"gpt_icon":0},{"id":"2602322575","title":"超1亿美元！蛋白降解剂“吸金”，强生、诺华、谷歌都来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2602322575","media":"医药魔方","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602322575?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:43","pubTimestamp":1767951793,"startTime":"0","endTime":"0","summary":"1月9日，致力于开发细胞外蛋白降解剂的EpiBiologics宣布完成1.07亿美元B轮融资，本轮融资由Google Ventures及Johnson & Johnson Innovation领投，Novartis Venture Fund等新投资者及Polaris Partners等现有投资者跟投。TrainTAC利用广泛的内化受体将膜蛋白和可溶性细胞外蛋白转运到溶酶体进行降解。EpiBiologics正在基于EpiTAC开发first-in-class及best-in-class靶向疗法，涉及肿瘤、免疫疾病等领域。在2025年AACR大会上，公司首次公布了c-Met EpiTAC双特异性抗体降解剂的临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109183655a706f830&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109183655a706f830&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1066051811.HKD","LU0124676726.USD","LU0477156797.USD","IE0005OL40V9.USD","GOOG","LU0211326755.USD","SG9999014906.USD","LU2211815571.USD","LU0354030511.USD","LU0965509010.AUD","SG9999014898.SGD","LU2063271972.USD","LU1868836914.USD","LU0289960550.SGD","LU0942090050.USD","IE00BYQQ9H92.USD","BK4587","LU2552382132.HKD","LU1074936037.SGD","IE00B42XCP33.USD","LU0545039389.USD","LU2462157665.USD","LU1145028129.USD","LU1303367103.USD","LU0256863811.USD","LU0203202063.USD","LU0342679015.USD","LU1429558221.USD","LU1127390331.HKD","LU0820561909.HKD","LU1366333091.USD","LU2129689514.USD","LU2552382215.SGD","LU0820561818.USD","LU1720051017.SGD","LU1057294990.SGD","LU1032466523.USD","LU0784385840.USD","LU1629891620.HKD","LU1366192091.USD","LU1201861165.SGD","SGXZ31699556.SGD","LU1803068623.USD","IE0009355771.USD","LU2458330169.SGD","LU2756315664.SGD","LU0114720955.EUR","LU0708994859.HKD","LU0690374961.EUR","LU0251132253.USD","LU0072462426.USD","GB00B4QBRK32.GBP","SG9999014914.USD","IE00BFSS8Q28.SGD","LU2764263039.SGD","LU2361044949.HKD","LU2125154935.USD","LU1116320737.USD","LU0080751232.USD","LU1035773651.USD","GOOGL","LU2896262040.SGD","LU0823434740.USD","LU1718418525.SGD","LU2505996509.AUD","IE00B3PB1722.GBP","LU1880398471.USD","LU1506573853.SGD","LU1267930573.SGD","IE0001KFT4U8.USD","LU0106261372.USD","LU0724617625.USD","LU2023250330.USD","LU1267930730.SGD","LU2347655156.SGD","LU0210536198.USD","LU1244550494.USD","LU2491050071.SGD","LU0882574139.USD","IE00B19Z3B42.SGD","LU0158827781.USD","LU1059921491.USD","BK4532","LU0316494557.USD","LU2168564065.EUR","LU2237443978.SGD","LU2065171311.SGD","IE00BK4W5M84.HKD","LU0354030438.USD","LU2054465674.USD","LU0980610538.SGD","LU1720051108.HKD","LU0256863902.USD","LU2456880835.USD","BK4579","IE00BBT3K403.USD","BK4525","LU0079474960.USD","LU0187121727.USD","LU0215105999.USD","IE00B5949003.HKD","LU0234570918.USD","BK4588","LU1267930490.SGD","LU0868494708.USD","IE00B7KXQ091.USD","LU2242650005.HKD","IE00B19Z8X17.USD","LU2077746001.SGD","LU2098885051.SGD","LU0130102774.USD","LU1929549753.HKD","LU1551013425.SGD","LU0109392836.USD","LU2404859667.USD","LU2265009873.SGD","IE00BVYPNW00.USD","LU1670628061.USD","LU2764262908.HKD","LU0061474705.USD","LU2505996681.GBP","LU1951198990.SGD","LU1674673428.USD","LU1732800096.USD","LU0096362180.USD","LU1023059063.AUD","BK4566","LU0786609619.USD","LU0878866978.SGD","LU1232071149.USD","LU2746668974.SGD","LU2357305700.SGD","LU0648000940.SGD","LU0345769631.USD","LU0788109477.HKD","LU2092937148.SGD","LU0353189763.USD","SG9999002224.SGD","BK4538","LU0466842654.USD","LU1642822529.SGD","LU2237443382.USD","LU2168564149.EUR","LU2087625088.SGD","LU0345770993.USD","LU1221951129.SGD","LU0109391861.USD","LU0211331839.USD","LU1917777945.USD","BK4568","IE00BDGV0183.EUR","LU0061475181.USD","LU0784384876.USD","LU1316542783.SGD","LU2242649171.HKD","LU2247934214.USD","LU1868836757.USD","LU2543165471.USD","LU1989764664.SGD","IE00BMPRXQ63.HKD","LU0689472784.USD","LU1699723380.USD","SG9999001440.SGD","IE00BLSP4239.USD","LU0985489474.SGD","SG9999015986.USD","LU0238689110.USD","IE00BKPKM429.USD","LU0557290698.USD","LU2360106780.USD","LU0823421333.USD","BK4602","LU2430703251.USD","LU1988902786.USD","IE00BLSP4452.SGD","LU0672654240.SGD","LU0170899867.USD","LU1496350502.SGD","IE00B19Z9505.USD","LU0528227936.USD","LU1815336760.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","LU0056508442.USD","IE0004445015.USD","IE00BGHQF631.EUR","LU0823434583.USD","LU1489326972.SGD","LU2361044865.SGD","LU0433182093.SGD","LU2264538146.SGD","LU2420271590.USD","LU2362540622.SGD","LU1162221912.USD","BK4548","LU1935043536.SGD","LU2089284900.SGD","LU0683600562.USD","BK4559","LU0964807845.USD","BK4507","LU2168563687.JPY","IE00B3T34201.USD","LU2089984988.USD","LU0312595415.SGD","IE0034235303.USD","LU0943347566.SGD","IE00BSNM7G36.USD","LU0077335932.USD","LU0210533765.USD","LU2023250843.SGD","LU0289941410.SGD","LU1585245621.USD","LU2237443465.HKD","LU1815333072.USD","LU2860962120.EUR","LU0957791311.USD","LU0784385170.HKD","LU2065169927.USD","LU0642271901.SGD","LU1839511570.USD","BK4585","LU0823421416.USD","LU2430703178.SGD","LU2764263203.CNY","LU2112291526.USD","LU1061106388.HKD","LU0957808578.USD","LU0345774631.USD","IE00BZ199S13.USD","LU0198837287.USD","LU0302445910.USD","IE00BJJMRY28.SGD","LU0314106906.USD","LU2028103732.USD","LU2362541513.USD","BK4598","IE00BN8TJ469.HKD","LU0432979614.USD","LU0158827948.USD","LU1221951046.USD","LU1894683264.USD","BK4543","IE00BFSS7M15.SGD","BK4503","LU0976567544.SGD","LU2191332357.HKD","LU2468319806.SGD","LU0784383803.USD","LU1934455194.USD","BK4553","LU1003077747.HKD","LU1066051498.USD","IE00B775H168.HKD","LU2271345857.HKD","LU1894683348.USD","LU0861579265.USD","LU2756315318.SGD","IE00BQXX3C00.GBP","LU0308772762.SGD","LU0211327993.USD","IE00BJJMRZ35.SGD","SG9999015978.USD","LU2108987350.USD","LU0061474960.USD","IE00BFXG0V08.USD","IE00BFMHRM44.USD","SG9999015945.SGD","LU1691799644.USD","LU2237438978.USD","LU0127658192.USD","LU2133065610.SGD","LU0708995401.HKD","LU0208291251.USD","SG9999014880.SGD","LU1116320901.HKD","LU1037948897.HKD","LU2097344357.USD","SG9999017495.SGD","LU0211328371.USD","IE00BWXC8680.SGD","LU1814569148.SGD","LU1880398554.USD","LU0795875169.SGD","LU2491050154.USD","LU0345768740.USD","LU0048573561.USD","BK4514","LU0070302665.USD","LU2471134952.CNY","IE0004091025.USD","LU0456855351.SGD","SG9999018857.SGD","LU1121112475.USD","LU0494093205.USD","LU1934455863.HKD","LU0096364046.USD","LU2244417387.USD","LU2361045086.USD","LU0082616367.USD","LU0157215616.USD","LU0348723411.USD","BK4533","LU0320765059.SGD","SGXZ99366536.SGD","LU2089283258.USD","LU0949170772.SGD","LU1974910355.USD","LU2471134796.USD","LU2360032135.SGD","LU1084165304.USD","LU1935043023.USD","LU2275660780.HKD","LU0154236417.USD","LU0098860793.USD","LU1046421795.USD","LU0476273544.USD","LU0949170426.SGD","LU1430594728.SGD","LU1323610961.USD","LU1633808545.USD","LU0889565833.HKD","LU2381873111.SGD","LU2750360641.GBP","LU2471134523.USD","LU0211326839.USD","IE00BHPRN162.USD","LU0048584097.USD","LU0276348264.USD","LU2106854487.HKD","LU2097829019.USD","LU2286300806.USD","IE00B2B36J28.USD","LU1153585028.USD","LU1778281490.HKD","LU2430703095.HKD","IE00BK4W5L77.USD","LU2023251221.USD","LU0912757837.SGD","LU0267386448.USD","LU0553294199.USD","LU2461242641.AUD","LU2023250504.SGD","BK4612","IE0002270589.USD","BK4504","LU1551013342.USD","LU0965508806.USD","LU0640476718.USD","LU1852331112.SGD","LU1951200564.SGD","BK4534","LU0210528500.USD","LU0795875086.SGD","LU2111349929.HKD","LU0345770308.USD","IE00B7SZLL34.SGD","LU1267930813.SGD","LU2097344431.USD","LU1043141123.HKD","IE00B3S45H60.SGD","IE00BMPRXR70.SGD","LU2237443549.SGD","LU0426412945.USD","LU2458330243.SGD","IE000M9KFDE8.USD","BK4554","LU0985320562.USD","LU2491049909.HKD","LU1037948541.HKD","LU2487616109.SGD","LU0444971666.USD","LU2417539215.USD","LU0314104364.USD","LU0070217475.USD","LU1934455277.USD","LU2552382058.USD","LU1571399168.USD","LU0128525929.USD","LU1301847155.USD","BK4581","LU0477156953.USD","LU0052756011.USD","LU0122379950.USD","LU0175139822.USD","LU1235294995.USD","LU0345769128.USD","LU2092627202.USD","LU1261432733.SGD","LU0738911758.USD","BK4007","IE00BJT1NW94.SGD","LU0107464264.USD","LU1069347547.HKD","LU2403377893.USD","LU0719512351.SGD","IE0034235188.USD","LU0310799852.SGD","BK4561","IE00BN29S564.USD","LU0345774391.USD","LU0053666078.USD","LU1196500208.SGD","LU2065170008.USD","LU1244550577.SGD","LU1119994496.HKD","LU1791710400.SGD","JNJ","LU1868837136.USD","SG9999015952.SGD","LU0496365809.HKD","LU0289739699.SGD","LU0323591593.USD","LU0130517989.USD","LU1548497426.USD","LU2129689605.HKD","LU2237443895.HKD","LU0094547139.USD","LU2592432038.USD","LU1732799900.SGD","LU1201861249.SGD","BK4576","LU0128525689.USD","IE00B4R5TH58.HKD","LU2326559502.SGD","IE00BJLML261.HKD","LU0444973449.USD","LU1496350171.SGD","IE00B775SV38.USD","LU2750360997.AUD","SG9999018865.SGD","IE00BJTD4N35.SGD","LU2213496289.HKD","LU1064131342.USD","LU0130103400.USD","LU0310800379.SGD","BK4573","LU2065171402.SGD","LU0225283273.USD","LU1035775433.USD","IE00BQXX3F31.USD","LU2168564495.EUR","LU2720916845.USD","LU0265550946.USD","LU1803068979.SGD","IE00BFXG1179.USD","LU1043141396.HKD","IE00BJTD4V19.USD","IE0004445239.USD","IE00BVYPNV92.GBP","LU2129689431.USD","LU0661504455.SGD","LU0345768153.USD","LU0006306889.USD","LU2237443622.USD","LU2236285917.USD","LU2250418816.HKD","LU2362541273.HKD","LU2602419157.SGD","NVS","LU1066053197.SGD","IE00BKDWB100.SGD","LU0882574055.USD","IE0004086264.USD","SG9999001077.SGD","LU0097036916.USD","LU1868837300.USD","LU2087621335.USD","LU0251142724.SGD","LU0320765646.SGD","BK4578","LU0994945656.USD","LU0310800965.SGD","LU1244550221.USD","LU0868494617.USD","IE00B1BXHZ80.USD","LU0265550359.USD","LU0251131958.USD","IE00BJJMRX11.SGD","LU0820562030.AUD","LU0353189680.USD","LU1923623000.USD","LU0690374615.EUR","LU1069344957.HKD","BK4592","LU0011850046.USD","LU1791710582.SGD","LU0417517546.SGD","LU0889566641.SGD","USJW.SI","SG9999002232.USD","LU2168564222.USD","LU1066051225.USD","LU0787776722.HKD","IE00BQXX3D17.EUR","GB00B4LPDJ14.GBP","LU0149725797.USD","IE00BZ1G4Q59.USD","BK4574","IE0009356076.USD","LU1823568750.SGD","IE0002141913.USD","LU2463028550.USD","LU0203347892.USD","IE00B19Z8W00.USD","LU0426417589.USD","IE00BMPRXN33.USD","SG9999000418.SGD","LU2404859741.USD","LU1868836591.USD","LU0965509283.SGD","LU1935042215.USD","BK4550","LU1670627923.USD","LU0203345920.USD","LU1914381329.SGD","IE00BKVL7J92.USD","LU1935042991.SGD","LU2746668461.USD","LU0130518102.USD","LU1804176565.USD","LU2125154778.USD","LU0965509101.SGD","IE00B1XK9C88.USD","LU0029864427.USD","SGXZ81514606.USD","BK4527","SGXZ51526630.SGD","IE00B5TLWC47.USD","LU1674673691.USD","LU0689626769.HKD","LU0058720904.USD","LU0648001328.SGD","LU1989764748.USD","LU0792757196.USD","IE00B4JS1V06.HKD","LU0068578508.USD","LU2471134879.HKD","LU0203201768.USD","LU1935042488.USD","LU1267930227.SGD","LU1280957306.USD","LU1435385759.SGD","LU1032955483.USD","LU0742534661.SGD","BK4077","LU0234572021.USD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2602006340","title":"千亿美元“专利悬崖”逼近！美股制药巨头瞄准收购新药，中小盘生物科技股迎来“超级溢价”投资盛宴？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602006340","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602006340?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:00","pubTimestamp":1767945631,"startTime":"0","endTime":"0","summary":"而多种因素共同促成了生物科技并购的爆发式增长。一些全球最畅销的药物正面临在关键地区失去专利保护的风险，这被业内称为“专利悬崖”。据计算，到2032年，畅销品牌专利保护期的丧失将造成至少1739亿美元的年销售额损失。生物科技板块近几年经历繁荣、衰退，然后又是繁荣新冠疫情期间，生物科技行业迅速成为投资者的热门之选。Loren表示，一系列利好数据也推高了生物科技股的估值。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390856.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股制药巨头瞄准收购新药，中小盘生物科技股迎来“超级溢价”投资盛宴？","news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LLY","NVS","BMY","PFE","NVO","GSK","AZN","MRK"],"gpt_icon":1},{"id":"2592192144","title":"特朗普标榜“大胜”：九大药企达成降价协议换取三年关税豁免","url":"https://stock-news.laohu8.com/highlight/detail?id=2592192144","media":"华尔街见闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592192144?lang=zh_cn&edition=full","pubTime":"2025-12-20 08:48","pubTimestamp":1766191729,"startTime":"0","endTime":"0","summary":"默沙东、诺华、葛兰素史克等九家药企签署协议后，特朗普称，今夏被政府盯上的17家药企中已有14家同意“大幅”降价。美商务部长暗示，剩余三家将在年末假期后宣布类似的协议。","market":"sg","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3761750","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3761750","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"特朗普标榜“大胜”：九大药企达成降价协议换取三年关税豁免","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","GSK","MRK"],"gpt_icon":1},{"id":"2592139231","title":"默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139231","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139231?lang=zh_cn&edition=full","pubTime":"2025-12-20 07:00","pubTimestamp":1766185200,"startTime":"0","endTime":"0","summary":"美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。在此次协议中，最受市场关注的是施贵宝的让利承诺。特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅下调药价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2acbaf8fbf691a451fa9ea170ee88816","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE000M9KFDE8.USD","LU2361044865.SGD","LU1261432733.SGD","IE00B4R5TH58.HKD","LU1989771016.USD","SNY","LU1868837300.USD","IE00BJJMRZ35.SGD","MRK","LU1093756325.SGD","LU0130517989.USD","SG9999014542.SGD","SGXZ57979304.SGD","BK4559","LU0098860793.USD","LU0980610538.SGD","LU1037948541.HKD","LU1868836591.USD","LU0106261372.USD","LU1116320737.USD","LU0477156953.USD","LU0237698245.USD","LU0114720955.EUR","LU1069347547.HKD","LU0265550946.USD","IE00BLSP4239.USD","LU1868836914.USD","LU1868836757.USD","LU2242652126.USD","IE00B1BXHZ80.USD","LU0211331839.USD","LU0266013472.USD","SG9999015341.SGD","JNJ","REGN","SG9999002224.SGD","BMY","LU1066053197.SGD","LU0320765646.SGD","LU1934455863.HKD","LU0122379950.USD","LU0306807586.USD","LU0456855351.SGD","LU2125154778.USD","LU1699723380.USD","LU1291159041.SGD","LU0208291251.USD","LU2360032135.SGD","LU0238689110.USD","SG9999014559.SGD","SG9999001440.SGD","GILD","LU1032466523.USD","BK4533","LU1074936037.SGD","LU1162221912.USD","LU1035773651.USD","LU1868837136.USD","IE00BFTCPJ56.SGD","LU0648001328.SGD","LU0861579265.USD","LU0096364046.USD","LU2133065610.SGD","LU0306806265.USD","LU1585245621.USD","IE00BN8TJ469.HKD","LU0225771236.USD","LU0203347892.USD","BK4585","LU0225284248.USD","SG9999013999.USD","LU1116320901.HKD","IE00BSNM7G36.USD","LU1023059063.AUD","LU2089984988.USD","LU1066051225.USD","LU1670710661.SGD","LU2023250504.SGD","LU1066051811.HKD","LU0070302665.USD","LU1983299246.USD","LU1989772923.USD","LU2106854487.HKD","SG9999014567.USD","LU2361045086.USD","LU0289739699.SGD","LU0234572021.USD","LU0868494617.USD","SG9999014575.USD","LU0058720904.USD","LU1430594728.SGD","BK4516","BK4534","LU1201861249.SGD","SG9999002232.USD","BK4550","GSK","LU1057294990.SGD","LU0882574055.USD","LU1037948897.HKD","LU1941712348.USD","LU0006306889.USD","LU1061106388.HKD","SG9999001176.SGD","SG9999015358.SGD","LU0965509283.SGD","LU0985481810.HKD","LU2468319806.SGD","LU0985320562.USD","LU1323610961.USD","LU0265550359.USD","LU0321505439.SGD","IE0009355771.USD","IE00BFXG1179.USD","04332","BK4581","LU1941712264.USD","LU0203345920.USD","LU2242646821.SGD","LU2461242641.AUD","BK4532","LU1917777945.USD","LU0965509101.SGD","LU1093756168.USD","LU2112291526.USD","LU1989772840.SGD","AMGN","LU1974910355.USD","LU0965508806.USD","LU2125154935.USD","LU1929549753.HKD","LU1718418525.SGD","LU2361044949.HKD","LU0321505868.SGD","LU1571399168.USD","NVS","LU1934455277.USD","IE0002141913.USD","LU2324357040.USD","BK4007","LU0267386448.USD","LU0061475181.USD","LU0320765489.SGD","ABBV","IE00B2B36J28.USD","AZN","ROG","LU1670711040.USD","SG9999001176.USD","LU1670711123.USD","BK4588","IE00BLSP4452.SGD","LU0965509010.AUD","IE00BBT3K403.USD","LU2023250843.SGD","LU1934455194.USD","IE00BJT1NW94.SGD","LU0130102774.USD","LU1670710588.SGD","LU1066051498.USD"],"gpt_icon":1},{"id":"1190397083","title":"美国官员称与安进、施贵宝、罗氏旗下基因泰克、吉利德、葛兰素史克、默沙东、诺华、赛诺菲和博瑞诺的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1190397083","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190397083?lang=zh_cn&edition=full","pubTime":"2025-12-20 03:22","pubTimestamp":1766172127,"startTime":"0","endTime":"0","summary":"美国官员称与安进、施贵宝、罗氏旗下基因泰克、吉利德、葛兰素史克、默沙东、诺华、赛诺菲和博瑞诺的交易","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU1323610961.USD","IE00B2B36J28.USD","LU0122379950.USD","GILD","BK4585","LU1116320901.HKD","BIIB","LU2089984988.USD","LU0267386448.USD","SG9999014567.USD","LU2361045086.USD","LU1670711123.USD","SG9999002224.SGD","LU0823416689.USD","IE00BQJZX424.USD","IE00BSNM7G36.USD","SNY","LU1023059063.AUD","LU0114720955.EUR","SG9999014559.SGD","BK4534","LU1778281490.HKD","LU2023250504.SGD","LU0980610538.SGD","LU1974910355.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0203345920.USD","LU1868836757.USD","LU0266013472.USD","LU0289739699.SGD","LU2125154778.USD","LU0321505868.SGD","LU1098665638.USD","LU0234572021.USD","LU1670710661.SGD","SG9999001176.SGD","LU1057294990.SGD","LU1162221912.USD","LU1309081286.SGD","IE00B3T34201.USD","IE0002270589.USD","BK4599","LU0130517989.USD","LU1064927863.SGD","LU1868837300.USD","LU1839511570.USD","LU2324357040.USD","LU0225771236.USD","LU1571399168.USD","LU2361044865.SGD","SGXZ57979304.SGD","LU0225284248.USD","LU0106261372.USD","LU0109394709.USD","LU0234570918.USD","LU1228905540.USD","LU0965509101.SGD","LU1868837136.USD","SG9999015978.USD","LU1934455194.USD","LU0320765992.SGD","IE00BWDBJ516.SGD","BK4568","MRK","SG9999014575.USD","SG9999015945.SGD","IE00BLSP4239.USD","LU1116320737.USD","SG9999015341.SGD","LU0161305163.EUR","LU1037948897.HKD","LU1066051498.USD","LU1941712348.USD","LU0321505439.SGD","LU0237698245.USD","IE00BLSP4452.SGD","LU0477156953.USD","LU0985481810.HKD","IE00BKVL7J92.USD","LU2242646821.SGD","LU0265550359.USD","LU0965508806.USD","LU1941712264.USD","LU2133065610.SGD","LU0238689110.USD","BK4516","BK4581","LU0058720904.USD","LU0545562505.USD","LU1035777561.USD","SG9999015952.SGD","LU1202635105.USD","IE00B1BXHZ80.USD","LU0306806265.USD","LU0211331839.USD","LU2112291526.USD","LU0006306889.USD","LU2023250843.SGD","BK4139","NVS","LU0203347892.USD","LU1699723380.USD","LU0648001328.SGD","LU2468319806.SGD","LU0109981661.USD","LU1670710588.SGD","IE00B19Z3581.USD","LU1989771016.USD","IE0009355771.USD","LU1302929846.USD","IE000M9KFDE8.USD","LU1487256676.USD","IE0034235071.USD","LU1670756490.USD","BK4550","LU1989772923.USD","IE00BZ1G4Q59.USD","LU1069347547.HKD","BK4578","BK4559","BK4532","IE00BJJMRZ35.SGD","LU1066051225.USD","LU1061106388.HKD","LU2087621335.USD","LU2361044949.HKD","RHHBY","GSK","LU0061475181.USD","LU2106854487.HKD","LU1917777945.USD","BK5011","LU1291159041.SGD","LU1989772840.SGD","LU1645745479.HKD","IE00BJT1NW94.SGD","LU0971552673.USD","LU1929549753.HKD","LU0320765646.SGD","LU1481600234.SGD","LU1718418525.SGD","LU2360032135.SGD","LU1670711040.USD","LU1046248800.SGD","LU0965509283.SGD","LU1015430645.USD","BK4588","LU2461242641.AUD","BK4566","LU1066053197.SGD","LU0130102774.USD","LU1983299246.USD","SG9999015358.SGD","LU1400636491.USD","IE0002141913.USD","LU0985320562.USD","LU1400636574.HKD","LU1400636657.SGD","LU1674673428.USD","LU0868494617.USD","IE00B19Z3B42.SGD","LU1093756325.SGD","LU1674673691.USD","04332","LU1201861249.SGD","LU0456855351.SGD","LU0965509010.AUD","LU1934455863.HKD","LU0208291251.USD","LU0861579265.USD","BK4583","SG9999014542.SGD","LU0882574055.USD","LU1481599808.USD","LU1868836591.USD","LU1228905037.USD","LU1585245621.USD","IE00BN8TJ469.HKD","LU1934455277.USD","LU1261432733.SGD","LU1066051811.HKD","LU1093756168.USD","IE00B7SZLL34.SGD","LU0971552830.HKD","IE00BFXG1179.USD","BK4533","LU1074936037.SGD","LU1868836914.USD","LU1035773651.USD","SG9999001176.USD","LU1037948541.HKD","LU0320765489.SGD","LU1430594728.SGD","BMY","BK4007","LU0070302665.USD","LU0098860793.USD","SG9999002232.USD","LU1032466523.USD","SG9999013999.USD","SG9999001440.SGD","LU2242652126.USD","IE00BBT3K403.USD","LU0265550946.USD","LU0575583348.USD","AMGN","LU0306807586.USD","LU2125154935.USD","SG9999015986.USD","LU0096364046.USD"],"gpt_icon":0},{"id":"2591649704","title":"中国同辐(01763)附属原子高科与诺华公司签署商业合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649704","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591649704?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:15","pubTimestamp":1765804518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国同辐(01763)发布公告，本公司附属公司原子高科股份有限公司(原子高科)与诺华医药科技(浙江)有限公司(诺华公司)正式签署派威妥®(镥[177Lu]特昔维匹肽注射液)商业合作协议(商业合作协议)。派威妥® 是国内首个且目前唯一获批的靶向PSMA的放射配体疗法药物，主要用于治疗晚期前列腺癌，未来将为患者提供延长生命并改善生活质量的全新核药治疗方案。此次签约开启了双方在创新核药产品派威妥®方面的战略合作，原子高科将凭藉在放射性药物领域的多年合规运营经验，与诺华公司强强联合，为医疗机构和患者提供定制化的派威妥®产品供应与解决方案，以惠及更多的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0208291251.USD","IE0002141913.USD","LU0211331839.USD","LU0320765489.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4578","NVS","IE00BJJMRZ35.SGD","BK1222","LU0070302665.USD","IE0009355771.USD","01763","BK4007","BK4585","BK4588","BK4532","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":0.0332},{"period":"1month","weight":0.1458},{"period":"3month","weight":0.3298},{"period":"6month","weight":0.3024},{"period":"1year","weight":0.5513},{"period":"ytd","weight":0.1995}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日根据瑞士法律注册成立，为股份公司。公司是一家创新医药公司，从事研究、开发、制造、分销、营销和销售范围广泛的医药产品。它专注于核心治疗领域，包括心血管、肾脏和代谢疾病、免疫学、神经科学和肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.007884},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.00534},{"month":3,"riseRate":0.52,"avgChangeRate":0.001443},{"month":4,"riseRate":0.72,"avgChangeRate":0.018717},{"month":5,"riseRate":0.68,"avgChangeRate":0.009252},{"month":6,"riseRate":0.576923,"avgChangeRate":0.011998},{"month":7,"riseRate":0.692308,"avgChangeRate":0.011407},{"month":8,"riseRate":0.423077,"avgChangeRate":0.001152},{"month":9,"riseRate":0.692308,"avgChangeRate":0.009673},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.013123},{"month":11,"riseRate":0.615385,"avgChangeRate":0.016411},{"month":12,"riseRate":0.692308,"avgChangeRate":0.020635}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}